Lisata Therapeutics Inc. Watch

from 8-K 7 pages Plan of reorganization, merger, acquisition or similar

from 8-K 10 pages Plan of reorganization, merger, acquisition or similar

from 8-K 10 pages Plan of reorganization, merger, acquisition or similar

from 8-K 101 pages Plan of reorganization, merger, acquisition or similar

from 8-K 94 pages Interest Purchase Agreement Among Hitachi Chemical Co. America, Ltd., Pct, LLC, a Caladrius Company, and Caladrius Biosciences, Inc., Dated as of March 16, 2017 – 1 –

from 8-K 94 pages Interest Purchase Agreement Among Hitachi Chemical Co. America, Ltd., Pct, LLC, a Caladrius Company, and Caladrius Biosciences, Inc., Dated as of March 16, 2017 – 1 –

from DEFA14A 94 pages Interest Purchase Agreement Among Hitachi Chemical Co. America, Ltd., Pct, LLC, a Caladrius Company, and Caladrius Biosciences, Inc., Dated as of March 16, 2017 – 1 –

from DEFA14A 94 pages Interest Purchase Agreement Among Hitachi Chemical Co. America, Ltd., Pct, LLC, a Caladrius Company, and Caladrius Biosciences, Inc., Dated as of March 16, 2017 – 1 –

from 8-K 84 pages Agreement and Plan of Merger Between Neostem, Inc., NBS Acquisition Sub I, Inc., NBS Acquisition Sub II, LLC, California Stem Cell, Inc., and Jason Livingston as the Csc Representative

from 8-K 5 pages Amendment to Equity Purchase Agreement

from DEFA14A 30 pages Equity Purchase Agreement

from 8-K 30 pages Equity Purchase Agreement

from 8-K 133 pages Agreement and Plan of Merger Between Neostem, Inc., Amo Acquisition Company I, Inc., Amo Acquisition Company II, LLC, and Amorcyte, Inc., Dated as of July 13, 2011

from 425 133 pages Agreement and Plan of Merger Between Neostem, Inc., Amo Acquisition Company I, Inc., Amo Acquisition Company II, LLC, and Amorcyte, Inc., Dated as of July 13, 2011

from 8-K 109 pages Agreement and Plan of Merger

from 425 109 pages Agreement and Plan of Merger

from 10-Q 2 pages Plan of reorganization, merger, acquisition or similar

from 8-K 70 pages Agreement and Plan of Merger by and Among Neostem, Inc., Cbh Acquisition LLC, China Biopharmaceuticals Holdings, Inc. and China Biopharmaceuticals Corp. November 2, 2008

from 8-K 38 pages This Share Exchange Agreement (This “Agreement”) Is Made and Entered Into as of This 2nd Day of November 2008, by and Among Neostem, Inc., a Delaware Corporation (“Neostem”), China Stemcell Medical Holding Limited, a Hong Kong Company (The "Hk Entity"), Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine Limited Liability Company, a China Limited Liability Company (The "Institute Co. ") (Its Preexistence Is Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine, “Institute”), Beijing Huameitai Bio-Technology Limited Liability Company (“Wfoe”) and Zhao Shuwei (“Hk Shareholder”)